Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;18(17):2439-51.
doi: 10.2174/13816128112092439.

Advances in biomarker research for pancreatic cancer

Kruttika Bhat  1 , Fengfei Wang, Qingyong Ma, Qinyu Li, Sanku Mallik, Tze-Chen Hsieh, Erxi Wu
Affiliations
Review

Advances in biomarker research for pancreatic cancer

Kruttika Bhat et al. Curr Pharm Des. 2012.

Abstract

Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical. Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Genetic progression model for PC [, –41].
See this image and copyright information in PMC

References

    1. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta. 2011;1815(1):44–64. - PMC - PubMed
    1. Verma M. Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology. Cancers. 2010;2:1830–1837. - PMC - PubMed
    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on pre-mature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236. - PubMed
    1. Fry LC, Monkemuller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883–890. - PubMed
    1. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther. 2006;5:787–796. - PubMed

Publication types